

Scalable Oral Drug Candidate on the Growing Obesity Market

Pila Pharma AB (“Pila Pharma” or “the Company”) is developing the drug candidate XEN-D0501 for obesity, type 2 diabetes, and erythromelalgia, an orally administered, small-molecule TRPV1 antagonist aiming to reduce hyperactive inflammation linked to metabolic disorders. The candidate is considered scalable and provides a differentiated alternative to current therapies, expected to be essential in making obesity treatment more accessible. Analyst Group argues that the potential relative to the associated risks is not reflected in the current valuation, and based on an rNPV model, a present value of SEK 6.3 per share is derived in a Base scenario.

▪ An Alternative Expected to Gain Market Share

Following an oversubscribed share issue of 293.5%, indicating strong investor interest, Pila Pharma has expanded the portfolio to include obesity. Pila Pharma’s XEN-D0501 offers potential advantages over current obesity treatments through its oral small-molecule profile, enabling simpler manufacturing and more efficient scale-up. This may contribute to making obesity therapy more accessible to large patient populations. Using conservative assumptions, we estimate non-risk-adjusted peak sales royalties of approx. SEK 1.1bn annually within obesity.

▪ Multiple Licensing Deals in Emerging Obesity Treatments

The increasing focus on new, scalable obesity drugs has driven a rise in licensing and acquisition activity, particularly in oral small-molecule programs with alternative mechanisms of action such as Pila Pharma’s. This trend reflects high risk appetite and a drive to secure differentiated technologies at an early stage. Analyst Group estimates that the Company signs a licensing agreement with a partner in year 2028, following completed phase IIa studies in obesity and type 2 diabetes, with a deal value of USD 300m.

▪ Diversified Portfolio

Beyond obesity, the pipeline includes indications targeting type 2 diabetes and the pain-related disease erythromelalgia. In type 2 diabetes, two phase IIa studies have been conducted, showing a favorable safety profile and effects on improved glucose tolerance and enhanced insulin response. The candidate has been tested in over 300 patients in total, with good safety, which lowers the risk ahead of upcoming trials. For type 2 diabetes, non-risk-adjusted peak sales royalties are estimated at SEK 1.4bn annually, and for erythromelalgia SEK 230m.

▪ Attractive Valuation Relative to Potential

Drug development carries high risk due to the binary nature of clinical trials; however, Analyst Group assesses that the potential of Pila Pharma’s portfolio relative to risk is not reflected in the current valuation. Through an rNPV model, which includes an estimated capital injection of approximately SEK 45m from T02 and the resulting increase in number of shares, a present value per share of SEK 6.3 is indicated in a Base scenario. This is further supported by a relative valuation showing that Pila Pharma is valued low compared to peers.

VALUATION RANGE

Bear
SEK 1.1


Base
SEK 6.3

Bull
SEK 10.6

KEY INFORMATION

Share Price (2026-01-13)	1.75
Shares Outstanding	42,084,415
Market Cap (SEKm)	73.6
Net cash(-)/debt(+)	-16.0 ¹
Enterprise Value (SEKm)	57.6
List	Nasdaq First North Growth Market
Quarterly report 4 2025	2026-02-26

SHARE PRICE DEVELOPMENT



OWNERS (SOURCE: THE COMPANY, 2025-12-31)

OWNER	PERCENTAGE
Virala Oy Ab	16.3%
Dorte X. Gram	14.2%
The Mohsen Zaki Fahmi and Maria Gabriella Fahmi living trust	3.2%
BNY Mellon Sa/Nv For Jyske	2.8%
Saxo Bank A/S Client Assets	2.2%

Estimates (SEKm)	2026E	2027E	2028E	2029E
Riskadjust. revenues (type 2 diabetes)	0.0	0.0	0.0	0.0
Riskadjust. revenues (obesity)	0.0	0.0	0.0	0.0
Riskadjust. revenues (erythromelalgia)	0.0	0.0	0.0	0.0
Riskadjust. revenues (license deal)	0.0	0.0	55.8	0.0
Total riskadjust. Revenues	0.0	0.0	55.8	0.0
Operational expenses	-36.0	-11.0	-6.0	-6.0
EBIT	-36.0	-11.0	49.8	-6.0
EBIT margin (adj.)	neg.	neg.	89.3%	neg.

¹Estimated cash position based on cash at end of H1-25, net proceeds from the rights issue after transaction costs, and estimated expenses during H2-25.

Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, **Pila Pharma AB** (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2026). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.